CM
TWST icon

Castleark Management’s Twist Bioscience TWST Stock Holding History

Castleark Management’s Portfolio TWST Stock Details TWST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-69,520
Closed -$3.14M – 333
2024
Q3 		$3.14M Sell
69,520
-87,860
-56% -$4.18M 0.13% 149
2024
Q2 		$7.76M Buy
157,380
+10,750
+7% +$438K 0.32% 59
2024
Q1 		$5.03M Buy
146,630
+15,470
+12% +$558K 0.21% 118
2023
Q4 		$4.83M Buy
+131,160
New +$3.03M 0.21% 116
2019
Q4 		– Sell
-142,416
Closed -$3.4M – 392
2019
Q3 		$3.4M Buy
142,416
+14,672
+11% +$427K 0.14% 181
2019
Q2 		$3.71M Buy
+127,744
New +$3.38M 0.14% 173

Other funds holding TWST

Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Castleark Management's TWST Position: Q4 2024 in Review

Castleark Management sold out of Twist Bioscience (TWST) in Q4 2024, closing a stake of 69,520 shares — an estimated $3.14M sold.

Castleark Management first reported a position in TWST in Q2 2019 and held it in 6 quarters. The position peaked at $7.76M in Q2 2024. 246 funds tracked by Wall St. Rank hold TWST as of Q4 2024.

  • Castleark Management reported no remaining Twist Bioscience position as of Q4 2024 after selling out during the quarter.
  • Castleark Management sold 69,520 Twist Bioscience shares in Q4 2024, an estimated $3.14M.
  • Castleark Management first reported a position in Twist Bioscience in Q2 2019 and held it in 6 quarters.
  • Castleark Management's Twist Bioscience position peaked at $7.76M in Q2 2024.
  • 246 funds tracked by Wall St. Rank held Twist Bioscience as of Q4 2024.

Based on Castleark Management's 13F filing for Q4 2024, filed 18 Feb 2025.